ECSP014130A - Compuestos heterociclicos como ligandos de los receptores gaba. - Google Patents

Compuestos heterociclicos como ligandos de los receptores gaba.

Info

Publication number
ECSP014130A
ECSP014130A EC2001004130A ECSP014130A ECSP014130A EC SP014130 A ECSP014130 A EC SP014130A EC 2001004130 A EC2001004130 A EC 2001004130A EC SP014130 A ECSP014130 A EC SP014130A EC SP014130 A ECSP014130 A EC SP014130A
Authority
EC
Ecuador
Prior art keywords
agonists
ligandos
gaba
receivers
compounds
Prior art date
Application number
EC2001004130A
Other languages
English (en)
Inventor
George Maynard
Daniel Yohannes
Jun Yuan
Linghong Xie
Kungae Lee
Manuka Ghosh
George Luke
Xiaojun Liu
Albert Vincent Lawrence
Kevin Currie
Zhe-Qing Wang
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Publication of ECSP014130A publication Critical patent/ECSP014130A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Catalysts (AREA)
  • Pyridine Compounds (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Lo que se divulga en el presente son compuestos heterocíclicos de la fórmula. Y sales farmacéuticas aceptables de la misma cuya característica es que las variables A, V, Y, J, E, X, T, G, Q, W, Z, b, n y m se definen en el presente. Estos compuestos son agonistas, antagonistas o agonistas invertidos?? Altamente selectivos para los receptores cerebrales GABAA O pro-fármacos de agonistas, antagonistas o agonistas invertidos para los receptores cerebrales GABAA.
EC2001004130A 2000-08-07 2001-08-07 Compuestos heterociclicos como ligandos de los receptores gaba. ECSP014130A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22366900P 2000-08-07 2000-08-07

Publications (1)

Publication Number Publication Date
ECSP014130A true ECSP014130A (es) 2002-03-25

Family

ID=22837525

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2001004130A ECSP014130A (es) 2000-08-07 2001-08-07 Compuestos heterociclicos como ligandos de los receptores gaba.

Country Status (19)

Country Link
US (2) US6653471B2 (es)
EP (1) EP1325006A2 (es)
JP (1) JP2004505942A (es)
KR (1) KR20030036678A (es)
CN (1) CN1468241A (es)
AU (1) AU2001285401A1 (es)
BR (1) BR0113120A (es)
CA (1) CA2420967A1 (es)
CO (1) CO5310576A1 (es)
EC (1) ECSP014130A (es)
HN (1) HN2002000193A (es)
IL (1) IL154310A0 (es)
MX (1) MXPA03001186A (es)
PA (1) PA8524601A1 (es)
PE (1) PE20020275A1 (es)
PY (1) PY0119496A (es)
TN (1) TNSN01122A1 (es)
UY (1) UY26874A1 (es)
WO (1) WO2002012442A2 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005500253A (ja) * 2001-02-23 2005-01-06 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド トロンビン受容体アンタゴニストとしてのアミノメチルピロロキナゾリン化合物
AU2003212979A1 (en) * 2002-02-07 2003-09-02 Neurogen Corporation Substituted fused pyrazolecarboxylic acid arylamides and related compounds
AR045037A1 (es) 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
FR2857363B1 (fr) * 2003-07-10 2007-09-07 Aventis Pharma Sa 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c] pyridines substituees compositions les contenant et utilisation
MX2007007919A (es) * 2004-12-31 2008-01-22 Reddy Us Therapeutics Inc Nuevos derivados de bencilaminas como inhibidores de la proteina de transferencia de colesteril-ester(cetp).
US7737279B2 (en) 2005-05-10 2010-06-15 Bristol-Myers Squibb Company 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
US8583926B1 (en) 2005-09-19 2013-11-12 Jpmorgan Chase Bank, N.A. System and method for anti-phishing authentication
WO2007053352A2 (en) * 2005-10-28 2007-05-10 Wyeth Pyrroloquinolinone derivatives as 5-hydroxytryptamine-6 ligands
US20070099911A1 (en) * 2005-10-28 2007-05-03 Wyeth Pyrroloquinolinone derivatives as 5-hydroxytryptamine-6 ligands
US20090075968A1 (en) * 2005-12-29 2009-03-19 Junichi Sakaki CETP inhibitors
AU2007247385B2 (en) 2006-05-10 2011-07-14 Novartis Ag Bicyclic derivatives as CETP inhibitors
CN101443324A (zh) * 2006-05-11 2009-05-27 诺瓦提斯公司 作为cetp抑制剂的苄胺衍生物
AU2007321283A1 (en) * 2006-11-15 2008-05-22 Novartis Ag Heterocyclic derivatives as CETP inhibitors
EP2190850A4 (en) * 2007-07-03 2011-03-09 Univ British Columbia DELTAF508 CFTR DELTAF508 DELTAFLECTIVE TRANSPORTATION MOLECULES
AU2009257602B2 (en) * 2008-06-10 2015-10-08 Abbvie Inc. Novel tricyclic compounds
KR101354416B1 (ko) * 2009-05-07 2014-02-19 에프. 호프만-라 로슈 아게 감마-아미노부티르산 조절제로서 이속사졸-피리딘 유도체
EP4782062A2 (en) 2009-12-01 2026-07-29 AbbVie Inc. Novel tricyclic compounds
JP2013512282A (ja) 2009-12-01 2013-04-11 アボット・ラボラトリーズ 新規三環式化合物
CN102712640A (zh) * 2010-01-12 2012-10-03 弗·哈夫曼-拉罗切有限公司 三环杂环化合物、其组合物和应用方法
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
BR112013033777A2 (pt) * 2011-03-15 2016-09-13 Abbvie Inc moduladores de receptor de hormônio nuclear
AU2012321345B2 (en) 2011-10-03 2016-03-17 The University Of Utah Research Foundation Application of 5-HT6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
TW201422590A (zh) 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
EP2935284A4 (en) 2012-12-21 2016-04-27 Abbvie Inc HETEROCYCLIC MODULATORS OF HORMONE NUCLEAR RECEPTORS
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
KR101612179B1 (ko) * 2013-04-19 2016-04-12 영남대학교 산학협력단 아미도피리딘올 유도체 또는 이의 약제학적 허용가능한 염을 유효성분으로 함유하는 암질환 예방 또는 치료용 약학조성물
WO2015125858A1 (ja) * 2014-02-24 2015-08-27 日本曹達株式会社 ヘテロアリール化合物およびその用途
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CA2976790C (en) 2015-02-20 2024-02-27 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN116270646A (zh) 2015-10-16 2023-06-23 艾伯维公司 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
KR102956194B1 (ko) 2018-05-04 2026-04-23 인사이트 코포레이션 Fgfr 억제제의 염
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為fgfr抑制劑之三環雜環
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11891377B1 (en) 2023-09-06 2024-02-06 King Faisal University Pyrrolo[3,2-c][2,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206415A (en) 1991-12-20 1993-04-27 Washington University Tricyclic steroid analogs
US5344626A (en) * 1992-06-26 1994-09-06 Minnesota Mining And Manufacturing Company Dual impregnated activated carbon
US5723462A (en) * 1996-04-26 1998-03-03 Neurogen Corporation Certain fused pyrrolecarboxamides a new class of GABA brain receptor ligands
GB9708945D0 (en) 1997-05-01 1997-06-25 Merck Sharp & Dohme Therapeutic agents
WO1998050385A1 (en) * 1997-05-08 1998-11-12 Merck Sharp & Dohme Limited SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS
GB9713707D0 (en) 1997-06-27 1997-09-03 Merck Sharp & Dohme Therapeutic agents
WO1999029319A2 (en) * 1997-12-09 1999-06-17 Neurosearch A/S Chemical compounds for use as anxiolytic agents and a method for the identification of anxiolytic compounds
AU2793199A (en) * 1998-02-26 1999-09-15 Neurogen Corporation 2-(het-)aryl-4-(cyclic amino substituted) heteroaryl fused pyridine derivatives,their preparation and their use as (ant-)agonists for gaba (a) brain receptors
US6103903A (en) * 1998-02-26 2000-08-15 Neurogen Corporation 4-(4-piperidylmethyhlamino) substituted heteroaryl fused pyridines: GABA brain receptor ligands

Also Published As

Publication number Publication date
US6949562B2 (en) 2005-09-27
BR0113120A (pt) 2004-06-22
WO2002012442A2 (en) 2002-02-14
KR20030036678A (ko) 2003-05-09
TNSN01122A1 (fr) 2005-11-10
UY26874A1 (es) 2002-03-22
CO5310576A1 (es) 2003-08-29
MXPA03001186A (es) 2004-04-20
PY0119496A (es) 2003-11-03
CA2420967A1 (en) 2002-02-14
HN2002000193A (es) 2002-11-05
CN1468241A (zh) 2004-01-14
US6653471B2 (en) 2003-11-25
US20030105081A1 (en) 2003-06-05
AU2001285401A1 (en) 2002-02-18
PE20020275A1 (es) 2002-04-09
PA8524601A1 (es) 2003-09-05
EP1325006A2 (en) 2003-07-09
IL154310A0 (en) 2003-09-17
US20040110778A1 (en) 2004-06-10
WO2002012442A3 (en) 2003-05-01
JP2004505942A (ja) 2004-02-26

Similar Documents

Publication Publication Date Title
UY26874A1 (es) Compuestos heterocíclicos como ligandos de los receptores gaba
NO20041504L (no) Lactamderivater som antagonister for humane 11CBY reseptorer.
UY26872A1 (es) Derivados de la 4- fenil piridina
ES2184070T3 (es) Derivados de oximas sustituidas utiles como antagonistas de la neuroquinina.
PA8657501A1 (es) Derivados de piperida y su uso como agentes antiinflamatorios
HN1999000149A (es) Derivados de 4,4-biarilpiperidina
ECSP066447A (es) Derivados de isoquinolina 1,4-disustituida como inhibidores raf-quinasa útiles para el tratamiento de enfermedades proliferativas
CR7812A (es) Compuestos de purina y usos de los mismos como ligandos de receptor de cannabinoides
CL2004000861A1 (es) Compuesto biciclico derivado de pirazol [4,3-d] pirimidin-7-ona o de pirazol [4,3-c] piridin-7-ona de formula definida, como ligando del receptor cannabinoide que actua como antagonista del receptor cb1; composicion farmaceutica que comprende al comp
AR003937A1 (es) Compuesto ciclico que tiene efecto antagonico al receptor de taquiquinina, proceso para producirlo y composicion farmaceutica que lo contiene.
ECSP066643A (es) PIRIDO [2,3-d] PIRIMIDINA-2,4-DIAMINAS COMO INHIBIDORES DE PDE 2
UY27918A1 (es) Derivados de benzodioxol
ECSP034830A (es) Derivados sustituidos de la ciclohexano-1,4- diamina
PA8577001A1 (es) Benzoilureas heterociclicamente sustituidas, procedimiento para su preparacion y su uso como farmacos
CO2022003062A2 (es) Compuestos heterocíclicos
CR8387A (es) Compuestos de pirazolilo e imidazolilo biciclicos y uso de los mismos
UY26729A1 (es) Alquilaminas heterocíclicas como antagonistas de los receptores muscarínicos
UY27851A1 (es) Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
CR8312A (es) Nuevas sulfonamidas como agentes fitosanitarios
PA8561501A1 (es) Lactamas como antagonistas de taquiquininas
CU24550B1 (es) Compuestos de aza-indazol útiles en lesiones de tendones y/o ligamentos
PA8589801A1 (es) Aminoalcoxiindoles
PA8587501A1 (es) Benzoxazinonas sustituidas y usos de las mismas
CR8092A (es) Pirazolopirimidinas sustituidas, procedimientos para su obtencion y el uso de las mismas para combatir hongos nocivos, asi como productos que las contienen
PA8486701A1 (es) Antagonistas de 5ht1 para terapia antidepresiva